PubMed Health⌕ Search

Biomedical subjects

W Danielczyk

Publications and source records attributed to W Danielczyk.

At least 55 records · Page 3Linked to original sources
PubMed1983

Symptoms and side effects in the course of Parkinson's disease.

From our investigations, we are tempted to assume that all types of akinesia, including "freezing", off-phases, Yo-Yoing and akinetic crises, are primarily symptoms of PD, while hyperkinesia, stretch spasms and pharmacotoxic psychosis are "side-effects". Therefore side-effects can be triggered by antiparkinsonian therapy while they will disappear after withdrawal of the drugs inducing them. Antiparkinson drugs alleviate major symptoms like akinesia and rigidity but sometimes and especially as reflection of advanced parkinsonism, might amplify minor symptoms (freezing, off-phases, Yo-Yoing), which then predominantly at high drug doses occur earlier and more intensively. Therefore, minor symptoms can be observed more frequently in the advanced stages of PD. Depressed phases belong to the symptom complex as is bradyphrenia and dizziness. Bradyphrenia is the psychic correlate to akinesia. Dementia, if at all is a symptom, but more likely this disease occurs occasionally in combination with parkinsonism.

Autonomic Nervous System Diseases↗
PubMed1982

[3 crises in Parkinson disease].

Three dangerous crises have great influence on the social relations of the Parkinson-patient and his life. Two of the three crises show the importance of the psychical component of the disease: In the beginning of the disease we often see a phase of "masked Parkinsonism" with serious depression. A hard break takes place in the patient's way of life. The second crisis is a phase of psychotic symptoms such as halucinations, paranoid ideas and mental confusion. This phase is a reaction between the disease and the antiparkinsonian medication. In the third, the akinetic crisis at last an extinction of physical mobility and psychic-reaction ability place takes. It is very important to start immediately with specific therapy in every one of the three crises.

Aged↗
PubMed1981

[Treatment of pharmacotoxic psychoses with clopenthixol in patients with Parkinson's disease (author's transl)].

Pharmacotoxic psychoses resulting from therapy of advanced Parkinson's disease can occur in up to 60% of the patients. Treatment must not be completely discontinued in such cases. Clopenthixol (Sordinol, Ciatyl) in small dosage has been shown to be much more effective than all other types of therapy in the management of those psychoses. In a group of 28 patients treated with clopenthixol the progression of Parkinson's disease was not quicker than a control group of 30 patients not treated with clopenthixol. Both groups were of similar age and at a similar stage of the disease.

Antiparkinson Agents↗
PubMed1980

Benign and malignant types of Parkinson's disease: clinical and patho-physiological characterization.

Parkinson's disease (P.D.) is characterized by two different types, a benign form found in 85% of patients and a malignant type in 15%. Computer tomography shows malignant patients, in the end stage of the disease process, to exhibit hydrocephalus internus and externus. Such patients exhibit early EEG-deterioration and pharmacotoxic psychosis. The application of neuroleptics to patients with P.D. is associated with an increase in the urinary excretion of acidic metabolites especially of 5-hydroxyindoleacetic acid. It is suggested, that this treatment might also be a useful therapeutic approach to optimizing the residual neuronal function in Parkinson's disease.

Aged↗
PubMed1979

[Familial striatal degeneration (author's transl)].

An extrapyramidal disorder occurring in three generations of a family (only males) is described The clinical features were progressive dementia and extrapyramidal signs without choreiform hyperkinesia. The youngest patient (onset of disease at the age of 22 years) showed tremor, rigidity, ataxia, convulsions, and myoclonus. The neuropathologic findings were characterized by isolated symmetrical degeneration of the corpus striatum and diffuse cortical atrophy without affecting other cerebrospinal neuronal systems. The clinical features of this familial disorder and its relation to other types of familial striatal degeneration and to the juvenile form of Huntington's chorea are discussed.

Adult↗
PubMed1979

[Acute pharmacotoxic psychoses in patients with chronic cerebral disorders].

269 patients suffering from progredient, chronic either primary or secundary cerebral diseases (Parkinson's disease, cerebral vascular diseases, cerebral atrophic dystrophy, Huntington's chorea, muliple sclerosis have been studied in the last two years. 44 of these patients developed pharmaco-toxic psychoses during drug treatment (low and medium dosis). The psycho-pathological rating resulted in an acute organic brain syndrome with predominance of confusion, sometimes progressing to delirium. EEG was changed during the psychotic stage. These changes cannot be decided from organic psychoses, which are not related to drugs. Patients with Parkinson's disease showed a relatively high incidence to psychoses during drug treatment (51.47%). In patients without Parkinson's disease, but on treatment with antidepressants, neuroleptics, diuretics and digitalis, pharmacotoxic psychoses only could be observed in 4.4% of the patients. However, the same group of patients showed an acute organic brain syndrome in 12.43%, when not on treatment. Combined treatment with L-DOPA plus peripherally acting decarboxylase inhibitors resulted in a high incidence to psychoses in idiopathic Parkinsonism but the same dosis produced this side effect only in a few patients with cerebral atrophic dystrophy. The ratio was 5:1 between the former group and the later one. That means, that L-DOPA is a much more psychotoxic substance in Parkinsonism when compared to other cerebral diseases. These pharmacotoxic psychoses could be correlated with the progredience of the disease. These pharmacotoxic psychoses are not only dependent from age and duration of treatment. Evidence exist, that there might be a correlation between the incidence for pharmacotoxic psychoses and the lack of surviving dopaminergic neurons in the nigro-striatal areas. Treatment with very low doses of neuroleptics suppresses pharmacotoxic psychoses but allow a further anti-Parkinson therapy which is of vital necessity.

Aged↗
PubMed1979

[Pharmacotoxic psychoses in patients with neurological disorders during old age (author's transl)].

23.3 per cent out of 180 old patients (age above 60 years, 71 y in the mean) suffering from chronic cerebral disorders (3 large groups of disease) developed pharmacotoxic psychoses. This relative high percentage can be explained by psychotoxic side effects of the modern antiparkinson-therapy. The incidence to psychotoxicity of combined L-Dopa seems to be less marked in patients without Parkinson's disease when compared to patients with progredient nigrostriatal degeneration. Toxic delirium as a result of treatment with antidepressants, diuretics and digitalis was observable only in a few percentage. This occurance was even less pronounced in comparison to acute developing exogene psychoses in the same group of patients when drugs were not administered.

Aged↗
PubMed1978

[The EEG in multiple sclerosis (author's transl)].

An abnormal EEG was obtained in altogether 76% of cases in a series of 172 patients with multiple sclerosis. Among the patients with minor neurological defects and a shorter duration of illness, only 26% of the EEGs were abnormal, whereas abnormal recordings were found in a high percentage of bedridden patients with severe neurological disturbances, irrespective of the duration of the illness, i.e. in 83% and 85% of these patients, subdivided according to illness of under or over 10 years' duration, respectively. Hence, severity of multiple sclerosis rather than length of the disease appears to be reflected in an abnormal EEG. Definite prognostic information concerning life expectancy cannot be otained from the EEG. Organic brain syndrom were closely correlated with the severity of EEG changes. Epileptic manifestations were clinically observed in 5.23% of the patients, all of whom manifested pathological EEG recordings.

Adult↗
PubMed1978

Dopamine-sensitive adenylate cyclase activity in the caudate nucleus and adrenal medulla in Parkinson's disease and in liver cirrhosis.

In human caudate nucleus and adrenal medulla dopamine-stimulated adenylate cyclase was measured. At a concentration of 100 microM dopamine, liver cirrhosis, carcinoma and therapy resistent parkinsonian patients showed decreased stimulation or even a reduction compared to controls. Therapy responding parkinsonian patients showed a decreased stimulation compared to controls, but this stimulation was significantly higher than in drug resistent patients.

Adenylyl Cyclases↗
PubMed1976

[The effect of fominoben on the EEG of Parkinson patients (author's transl)].

The intravenous or intramuscular application of Fominoben in parkinson patients with pathological EEG causes an intensification of general changes and localized slow wave groups. After a short increased psychic and motor excitability at the beginning of the injection there is a relaxed psychic and motor attitude. The passive tremor is also intensified during the injection but them markedly decreases. This improvement lasts about 4 to 6 hours.

Aged↗
PubMed1976

EEG, 5-HTP-metabolism and acupuncture.

Correlations between EEG-alterations and administration of 5-HT and 5-HTP in man are described. Age-dependence can be observed. Successful acupuncture produces EEG-alterations especially in younger patients as seen after exogene administration of 5-HT respectively 5-HTP i.v. Since biochemical indications for an increased 5-HT turnover during acupuncture of several acupuncture-points are evident further investigations should be carried out to enable reliable correlations.

5-Hydroxytryptophan↗